Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Status:
Completed
Trial end date:
2018-04-03
Target enrollment:
Participant gender:
Summary
To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in
combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose
(RP2D)